Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68,983 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study.
Zhang B, Li X, Ma Z, Zhang S, Song X, Gao H, Gong L, Hu Y, Wang M, Jiang D, Zhang C, Yuan X, Cao B, Zhang P, Nie L, Zhang Y, Chen X, Han L, Wei W, Shi Y. Zhang B, et al. Among authors: zhang s, zhang c, zhang p, zhang y. Thorac Cancer. 2022 Jun;13(11):1684-1690. doi: 10.1111/1759-7714.14444. Epub 2022 May 17. Thorac Cancer. 2022. PMID: 35579111 Free PMC article.
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.
Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, Song Y, Zhang C, Mei X, Cao B, Yang L, Cheng Y, Ying K, Sun T, Ren B, Yu Q, Liao Z, Pei Z, Wang M, Zhou J, Yu S, Feng G, Wan H, Wang H, Gao S, Wang J, An G, Geng Y, Ji Y, Yuan Y, Ma S, Jia Z, Hu M, Zhou H, Yu J, Sun X, Zhang L. Yang Y, et al. Among authors: zhang l, zhang c, zhang y. Transl Lung Cancer Res. 2019 Dec;8(6):989-999. doi: 10.21037/tlcr.2019.12.23. Transl Lung Cancer Res. 2019. PMID: 32010577 Free PMC article.
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
Li X, Zhang L, Jiang D, Wang Y, Zang A, Ding C, Zhao M, Su W, Zhang Y, Zhong D, Wu J, Zhang C, An G, Hu X, Cheng G, Wang H, Li Y, He X, Liu J, Liang L, Ding L, Mao L, Zhang S. Li X, et al. Among authors: zhang l, zhang c, zhang s, zhang y. Clin Cancer Res. 2020 Jul 1;26(13):3162-3171. doi: 10.1158/1078-0432.CCR-19-3064. Epub 2020 Feb 14. Clin Cancer Res. 2020. PMID: 32060099 Clinical Trial.
Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Zou Z, Hao X, Zhang C, Li H, Dong G, Peng Y, Ma K, Guo Y, Shan L, Zhang Y, Liang L, Gu Y, Xing P, Li J. Zou Z, et al. Among authors: zhang c, zhang y. Thorac Cancer. 2022 Jan;13(1):107-116. doi: 10.1111/1759-7714.14232. Epub 2021 Dec 1. Thorac Cancer. 2022. PMID: 34851035 Free PMC article.
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q, Ding C, Ai B, Gu Y, Yao Y, Sun H, Guo H, Zhang C, Song X, Li J, Xu B, Han Z, Song M, Tang T, Chen P, Lu H, Shui Y, Lou G, Zhang D, Liu J, Liu X, Liu X, Gao X, Zhou Q, Chen M, Zhao J, Zhong W, Xu Y, Wang M. Shi Y, et al. Among authors: zhang c, zhang d. Thorac Cancer. 2022 Feb;13(3):412-422. doi: 10.1111/1759-7714.14274. Epub 2021 Dec 21. Thorac Cancer. 2022. PMID: 34935288 Free PMC article.
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
Zou Z, Gu Y, Liang L, Hao X, Fan C, Xin T, Zhao S, Liu Z, Guo Y, Ma K, Li H, Zhang C, Shan L, Zhang Y, Dong G, Peng Y, Shen F, Song X, Christopoulos P, van der Wekken AJ, Okuda K, Ekman S, Xing P, Li J. Zou Z, et al. Among authors: zhang c, zhang y. Transl Lung Cancer Res. 2022 Dec;11(12):2495-2506. doi: 10.21037/tlcr-22-803. Transl Lung Cancer Res. 2022. PMID: 36636411 Free PMC article.
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.
Zhou Q, Zhang HL, Jiang LY, Shi YK, Chen Y, Yu JM, Zhou CC, He Y, Hu YP, Liang ZA, Pan YY, Zhuo WL, Song Y, Wu G, Chen GY, Lu Y, Zhang CY, Zhang YP, Cheng Y, Lu S, Wang CL, Zhou JY, Liu YP, He JX, Wang J, Wu YL. Zhou Q, et al. J Cancer Res Clin Oncol. 2023 Sep;149(12):10771-10780. doi: 10.1007/s00432-023-04923-8. Epub 2023 Jun 14. J Cancer Res Clin Oncol. 2023. PMID: 37316692 Free PMC article. Clinical Trial.
68,983 results
You have reached the last available page of results. Please see the User Guide for more information.